α7 nicotinic acetylcholine receptor agonist attenuates lipopolysaccharide-induced acute kidney injury in mice by reducing CCL2 expression in macrophages

Authors:

Abstract
Sepsis-induced acute kidney injury (AKI) is associated with a high mortality rate and presents a significant clinical challenge. However, effective treatment measures have not yet been established. The cholinergic anti-inflammatory pathway (CAP), a neural mechanism that regulates immune responses, has been reported to mitigate kidney injury. Although numerous studies have demonstrated the benefits of CAP activation prior to injury, its therapeutic potential after the onset of injury remains insufficiently explored. Therefore, this study aimed to evaluate the renoprotective effects of CAP activation after the onset of lipopolysaccharide (LPS)-induced AKI. LPS (5 mg/kg) was administered to C57BL/6 wild-type mice to induce AKI. Subsequently, GTS-21 (10 mg/kg), a selective α7 nicotinic acetylcholine receptor agonist, was administered to assess its anti-inflammatory and renoprotective effects. In RAW 264.7 and U937-derived macrophages, LPS-induced inflammation was treated with GTS-21, and its effects were evaluated. RNA sequencing was performed to elucidate the underlying molecular mechanisms. Even after the onset of LPS-induced AKI, the administration of GTS-21 demonstrated anti-inflammatory and renoprotective effects. In macrophages, the LPS-induced increase in TNF-α was suppressed by GTS-21 (50 μM) administration. Furthermore, CCL2 expression in macrophages might be involved in mediating these effects.
Funding Information
  • Japan Society for the Promotion of Science Grant-in-Aid for Young Scientists (22K16107, 23K15251)
  • Nagasaki University Grant for Co-creation Research
  • Japan Society for the Promotion of Science Grant-in-Aid for Research Activity Start-Up (21K20874, 24K23464)
  • Suzuken Memorial Foundation
  • Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care
  • Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research (22H03090)
  • Japan Agency for Medical Research and Development (JP22gm6210013)
  • Japan Science and Technology Agency (JST) FORES (JPMJFR210J)
  • MSD Life Science Foundation; Salt Science Research Foundation (1919)
  • SRF
  • Takeda Science Foundation; Astellas Foundation for Research on Metabolic Disorders
  • Tokyo Biochemical Research Foundation
  • Japan Kidney Association and Nippon Boehringer Ingelheim Joint Research Project
  • The Naito Foundation; Daiichi Sankyo Foundation of Life Science
  • The Uehara Memorial Foundation; Terumo Life Science Foundation

This publication has 56 references indexed in Scilit: